表紙
市場調查報告書

病情分析:慢性心力衰竭

Disease Analysis: Chronic Heart Failure

出版商 Datamonitor Healthcare 商品編碼 939972
出版日期 內容資訊 英文 82 Pages
商品交期: 最快1-2個工作天內
價格
病情分析:慢性心力衰竭 Disease Analysis: Chronic Heart Failure
出版日期: 2020年06月22日內容資訊: 英文 82 Pages
簡介

該報告是對慢性心力衰竭的調查。它提供有關藥物評估模型,市場動態和未來趨勢的信息,並介紹分析師和意見領袖的觀點。

內容

概述

疾病背景
  • 定義
  • 診斷方法
  • 風險因素
  • 症狀
  • 患者分類

    治療方法
    • 血管緊張素轉換□抑製劑
    • 血管緊張素受體拮抗劑
    • Beta阻止程序
    • 醛固酮拮抗劑
    • 超極化激活的環狀核甘酸門控通道阻滯劑
    • 血管緊張素受體中性溶□抑製劑
    • 其他毒品類別

      流行病學
      • 患病率方法

        市場上的藥品

        管道上的藥品

        主要監管運動
        • 阿斯利康的Farxiga被批准為首個SGLT-2抑製劑
        • Mesoblast加快了Revascor發射的開發速度
        • 美國FDA宣佈心力衰竭藥物開髮指南

          成功的可能性

          臨床試驗狀態
          • 每個階段的學生贊助商
          • 每個階段的研究贊助商
          • 最近事件

            藥物評估模型

            市場動態

            未來趨勢
            • 通過擴大領先品牌的治療藥物的使用來增加收益
            • Entresto的HFpEF藥物臨床試驗失敗,大大降低了收入增長的潛力
            • Entresto面臨與SGLT-2抑製劑的競爭
            • 與非專利藥競爭導致增長緩慢

              最近的動向和分析師的觀點

              未來的主要動向

              主要輿論領袖的觀點
              • 市場上的藥品
              • 管道上的藥品
              • 不受支持的需求

                不受支持的需求
                • HFpEF患者的治療
                • 改善HFrEF患者心臟收縮力的治療方法
                • 其他需求
                • 心臟病專家未滿足需求的排名

                  參考
                  • 處方藥信息

                    附錄

目錄
Product Code: DMKC0214650

Latest key takeaways

Chronic heart failure (CHF) is a progressive condition in which the heart muscle is unable to pump enough blood to meet the needs of the body. Datamonitor Healthcare estimates that in 2018, there were approximately 80.5 million cases in Asia, Europe, Latin America and the Caribbean, Northern America, and Oceania combined.

Datamonitor Healthcare forecasts the number of prevalent cases of CHF to increase by 9.1% between 2018 and 2027. These trends are driven by population demographics, as prevalence proportions were held constant throughout the forecast period.

The CHF market is expected to grow significantly over the next 10 years across the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK). The CHF market has predominantly been saturated with generics, which has limited the market revenue. Angiotensin-converting enzyme inhibitors remain the current standard-of-care therapy, and are used in every line of treatment except when using Entresto. However, there are a growing number of late-stage pipeline therapies, which, combined with the rising disease prevalence, will be the major drivers of market growth.

Despite initially encountering reimbursement challenges which led to a slower than expected uptake, Entresto reached blockbuster status in 2018 and maintained solid growth in 2019. Continued uptake of Entresto in the CHF market due to favorable recommendations in treatment guidelines and its proven ability to reduce mortality will be a key driver of market growth.

High prices of branded therapies will translate into high revenues, despite the large number of generics on the market. The SGLT-2 inhibitors, Jardiance and Farxiga, will be major market growth drivers, as they are expected to experience strong uptake in both diabetic and non-diabetic patients. SGLT-2 inhibitors are expected to capture the greatest market share in diabetic patients due to the convenience and cost-saving benefit of using one medication for two indications.

Generic entry of dapagliflozin, ivabradine, and sacubitril/valsartan will attenuate market growth towards the end of the forecast period.

The CHF market is becoming an increasingly active space, with 11 drug candidates currently in Phase III. Therapies in mid-to-late-stage development for CHF focus on a wide variety of targets, and include subcutaneous, oral, and injectable drug candidates.

The overall likelihood of approval of a Phase I CHF asset is 5.1%, and the average probability that a CHF drug advances from Phase III is 40%. CHF drugs, on average, take 10.5 years from Phase I to approval, compared to 10.0 years in the overall cardiovascular space.

Numerous high-impact upcoming events for drugs in the CHF space are expected in 2020, including Phase III trial results for a number of different drug candidates, such as data from SGLT-2 inhibitor Jardiance's Phase III EMPEROR-Reduced and -Preserved trials.

TABLE OF CONTENTS

OVERVIEW

  • Latest key takeaways

DISEASE BACKGROUND

  • Definition
  • Diagnosis
  • Risk factors
  • Symptoms
  • Patient segmentation

TREATMENT

  • Angiotensin-converting enzyme inhibitors
  • Angiotensin receptor blockers
  • Beta blockers
  • Aldosterone antagonists
  • Hyperpolarization-activated cyclic nucleotide-gated channel blockers
  • Angiotensin receptor-neprilysin inhibitors
  • Other drug classes

EPIDEMIOLOGY

  • Prevalence methodology

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

  • AZ To Adopt Indication-Based Pricing For Farxiga In Heart Failure
  • Novartis Seeks Entresto HFpEF Indication With Readjudicated PARAGON-HF Data
  • AstraZeneca's Farxiga Approval In Heart Failure A First For SGLT-2 Inhibitors
  • Mesoblast Sees Accelerated Path To Market For Revascor In Sickest Heart Failure Patients
  • Heart Failure Drug Development Might Need A Good Lawyer After US FDA Guidance

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

DRUG ASSESSMENT MODEL

MARKET DYNAMICS

FUTURE TRENDS

  • The high value of the CHF market will be driven by increased use of branded therapies
  • Entresto's failure in HFpEF patients will significantly limit revenue potential
  • Entresto faces competition from SGLT-2 inhibitors
  • Generic competition will offset growth in the CHF market

CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION

  • Mavacamten for CHF and Cardiomyopathies (May 11, 2020)
  • Mavacamten for CHF and Cardiomyopathies (March 30, 2020)
  • Vericiguat for CHF and Cardiomyopathies (March 28, 2020)
  • Elamipretide (Systemic Delivery) for CHF and Cardiomyopathies (February 18, 2020)
  • Jardiance for CHF and Cardiomyopathies (December 13, 2019)
  • Vericiguat for CHF and Cardiomyopathies (November 18, 2019)
  • Entresto for CHF and Cardiomyopathies (November 17, 2019)
  • Mavacamten for CHF and Cardiomyopathies (November 11, 2019)
  • Entresto for CHF and Cardiomyopathies (September 1, 2019)
  • Farxiga for CHF and Cardiomyopathies (September 1, 2019)
  • Mavacamten for CHF and Cardiomyopathies (August 31, 2019)
  • Farxiga for CHF and Cardiomyopathies (August 20, 2019)
  • Entresto for CHF and Cardiomyopathies (July 29, 2019)

KEY UPCOMING EVENTS

KEY OPINION LEADER INSIGHTS

  • Marketed drugs
  • Pipeline drugs
  • Unmet needs

UNMET NEEDS

  • Treatment for HFpEF patients
  • Therapies that improve cardiac contractility in patients with HFrEF
  • Other unmet needs
  • Cardiologist rankings of unmet needs in CHF

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Summary of treatment guidelines in CHF
  • Figure 2: Trends in prevalent cases of CHF, 2018-27
  • Figure 3: Overview of pipeline drugs for CHF in the US
  • Figure 4: Pipeline drugs for CHF, by company
  • Figure 5: Pipeline drugs for CHF, by drug type
  • Figure 6: Pipeline drugs for CHF, by classification
  • Figure 7: Probability of success in the CHF pipeline
  • Figure 8: Clinical trials in CHF
  • Figure 9: Top 10 drugs for clinical trials in CHF
  • Figure 10: Top 10 companies for clinical trials in CHF
  • Figure 11: Trial locations in CHF
  • Figure 12: CHF trials status
  • Figure 13: CHF trials sponsors, by phase
  • Figure 14: Datamonitor Healthcare's drug assessment summary for CHF
  • Figure 15: Market dynamics in CHF
  • Figure 16: Future trends in CHF
  • Figure 17: Mavacamten for CHF and Cardiomyopathies (May 11, 2020): Phase III - EXPLORER-HCM
  • Figure 18: Mavacamten for CHF and Cardiomyopathies (March 30, 2020): Phase II - MAVERICK-HCM
  • Figure 19: Vericiguat for CHF (March 28, 2020): Phase III - VICTORIA
  • Figure 20: Elamipretide (systemic delivery) for CHF (February 18, 2020): Natural History Study
  • Figure 21: Jardiance for CHF (December 13, 2019): Phase III - EMPERIAL-Preserved, Phase III - EMPERIAL-Reduced
  • Figure 22: Vericiguat for CHF (November 18, 2019): Phase III - VICTORIA
  • Figure 23: Mavacamten for CHF and Cardiomyopathies (November 11, 2019): Phase II - MAVERICK-HCM
  • Figure 24: Entresto for CHF (September 1, 2019): Phase III - PARAGON-HF
  • Figure 25: Farxiga for CHF (September 1, 2019): Phase III - DAPA-HF
  • Figure 26: Mavacamten for CHF and Cardiomyopathies (August 31, 2019): Phase II - PIONEER-OLE
  • Figure 27: Farxiga for CHF (August 20, 2019): Phase III - DAPA-HF
  • Figure 28: Entresto for CHF (July 29, 2019): Phase III - PARAGON-HF
  • Figure 29: Key upcoming events in CHF
  • Figure 30: Average scores of unmet needs in CHF in the US (n=40)
  • Figure 31: Average scores of unmet needs in CHF in Europe (n=41)

LIST OF TABLES

  • Table 1: Definition of HFrEF and HFpEF
  • Table 2: New York Heart Association functional classification based on severity of symptoms and physical activity
  • Table 3: Prevalent cases of CHF, 2018-27
  • Table 4: Marketed drugs for CHF
  • Table 5: Pipeline drugs for CHF in the US
  • Table 6: Historical global sales, by drug ($m), 2015-19
  • Table 7: Forecasted global sales, by drug ($m), 2020-24
  • Table 8: Mavacamten for CHF and Cardiomyopathies (May 11, 2020)
  • Table 9: Mavacamten for CHF and Cardiomyopathies (March 30, 2020)
  • Table 10: Vericiguat for CHF and Cardiomyopathies (March 28, 2020)
  • Table 11: Elamipretide (Systemic Delivery) for CHF and Cardiomyopathies (February 18, 2020)
  • Table 12: Jardiance for CHF and Cardiomyopathies (December 13, 2019)
  • Table 13: Vericiguat for CHF and Cardiomyopathies (November 18, 2019)
  • Table 14: Entresto for CHF and Cardiomyopathies (November 17, 2019)
  • Table 15: Mavacamten for CHF and Cardiomyopathies (November 11, 2019)
  • Table 16: Entresto for CHF and Cardiomyopathies (September 1, 2019)
  • Table 17: Farxiga for CHF and Cardiomyopathies (September 1, 2019)
  • Table 18: Mavacamten for CHF and Cardiomyopathies (August 31, 2019)
  • Table 19: Farxiga for CHF and Cardiomyopathies (August 20, 2019)
  • Table 20: Entresto for CHF and Cardiomyopathies (July 29, 2019)